Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights


-- Received $167 million in aggregate gross proceeds in April from initial public offering --– Advancing lead oncology program BMF-219, a small molecule irreversible menin inhibitor, toward IND filing in second half of 2021 --

Go here to see the original:
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights

Related Posts